Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, June 30, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2023 (2023-06-30): -516.32%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-328.95%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Scilex Holding Company
Market Cap
$33.63M
Return on Equity (ROE)
N/A
TTM Avg
-328.95%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$33.61M
Return on Equity (ROE)
-44.50%
TTM Avg
-16.33%
3Y Avg
-36.34%
5Y Avg
-33.52%
Market Cap
$33.29M
Return on Equity (ROE)
-238.24%
TTM Avg
203.84%
3Y Avg
55.01%
5Y Avg
16.87%
Market Cap
$32.93M
Return on Equity (ROE)
-86.96%
TTM Avg
-27.78%
3Y Avg
5.60%
5Y Avg
57.54%
Market Cap
$34.35M
Return on Equity (ROE)
329.02%
TTM Avg
154.76%
3Y Avg
265.18%
5Y Avg
128.71%
Market Cap
$32.79M
Return on Equity (ROE)
14.51%
TTM Avg
6.28%
3Y Avg
-34.57%
5Y Avg
-35.24%
Market Cap
$32.42M
Return on Equity (ROE)
-248.21%
TTM Avg
-991.58%
3Y Avg
-655.25%
5Y Avg
-438.62%
Market Cap
$34.97M
Return on Equity (ROE)
-154.06%
TTM Avg
-1.75%
3Y Avg
68.54%
5Y Avg
60.27%
Market Cap
$35.52M
Return on Equity (ROE)
-819.34%
TTM Avg
-116.46%
3Y Avg
-74.90%
5Y Avg
-96.78%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scilex Holding Company (SCLX) | $33.63M | N/A | -328.95% | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | -44.50% | -16.33% | -36.34% | -33.52% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | -238.24% | 203.84% | 55.01% | 16.87% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | -86.96% | -27.78% | 5.60% | 57.54% |
| Elutia Inc (ELUT)vs › | $34.35M | 329.02% | 154.76% | 265.18% | 128.71% |
| Nephros, Inc. (NEPH)vs › | $32.79M | 14.51% | 6.28% | -34.57% | -35.24% |
| HeartBeam, Inc. (BEAT)vs › | $32.42M | -248.21% | -991.58% | -655.25% | -438.62% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | -154.06% | -1.75% | 68.54% | 60.27% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | -819.34% | -116.46% | -74.90% | -96.78% |
| Nortech Systems Incorporated (NSYS)vs › | $31.52M | 2.91% | -2.27% | 5.52% | 6.87% |
ROE
N/A
ROA
-176.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-06-30 | -516.32% |
| 2023-03-31 | -406.05% |
| 2022-12-31 | -64.47% |
| 2021-09-30 | -45.03% |
| 2021-06-30 | -44.43% |
| 2021-03-31 | -41.69% |
